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Abstract 
Smoking protects against ulcerative colitis (UC), and treatment with nicotine patches has a beneficial symptomatic effect 
in patients with UC. To find an explanation for this response to nicotine in UC, we assessed the effects of nicotine on 
cytokine production by mononuclear cells (MNC). MNC were isolated from peripheral blood from healthy volunteers. 
Non-adherent MNC were preincubated with varying concentrations of nicotine or prednisolone for 24 h followed by addition 
of phytohemagglutinin (10~xg/ml). The concentrations of interleukin 2 (IL-2) and tumour necrosis factor-et (TNFa) in the 
supernatants were determined by ELISA. Nicotine as well as prednisolone caused a significant inhibition of IL-2 and TNFet 
production. The maximum inhibition caused by nicotine was about 50% of that caused by prednisolone and was reached at 
concentrations equivalent to nicotine levels measured in plasma of smokers. These results indicate that nicotine exerts its 
immunoregulatory role through modulation of the cytokine production by non-adherent mononuclear cells. 
Keywords: Nicotine; Cytokines; Human mononuclear cells 
I. Introduction 
During the last decade it has become clear that 
cigarette smoking not only increases the risk of 
developing cancer (Phillips, 1994) or cardiovascular 
Abbreviations: UC, Ulcerative colitis; MNC, Mononuclear 
cells; IBD, Inflammatory bowel disease; IL-2, Interleukin 2; 
TNFc~, Tumour necrosis factor alpha; DMEM, Dulbecco's modi- 
fied Eagles medium; PHA, Phytohemagglutinin; PBS, Phosphate 
buffered saline; FACS. Fluorescence-activated cell sorting 
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disease (Lepantalo and Lassila, 1991), but surpris- 
ingly, also has beneficial effects on some chronic 
diseases uch as Alzheimer disease (van Duijn et al., 
1991) and ulcerative colitis (Harries et al., 1982; 
Logan et al., 1984). Although the mechanisms under- 
lying these beneficial effects are unknown, there is 
evidence that smoking influences the cellular (Miller 
et al., 1982) as well as the humoral immune system 
(Fisher and KiSnig, 1994; Srivastava et al., 1991; 
Barton et al., 1990). 
Cigarette smoke contains a range of compounds 
with pharmacological ctivity. Of these compounds 
nicotine is the most important and it therefore seems 
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logical to assume it to be responsible for most of the 
immunoregulatory effects of cigarette smoke. Treat- 
ment of patients with active ulcerative colitis (UC), a 
form of inflammatory bowel disease, with nicotine 
patches proved to have a beneficial effect (Pullan et 
al., 1994). The application of transdermal nicotine 
signifcantly improved symptoms in these patients. 
Nicotine may therefore have anti-inflammatory prop- 
erties which could be important in the treatment of 
UC. 
Recent studies have indicated an important role 
for T-ceils in inflammatory bowel disease (IBD), 
especially in the initial phase of the inflammation. 
Cytokines produced by these cells play a key role in 
the pathogenesis of IBD. Elevated levels of TNFa 
and IL-2 have been reported in serum and stool of 
patients uffering from IBD, for most other cytokines 
there have been conflicting reports or they have not 
been adequately investigated (Sartor, 1994). 
In order to find an explanation for the beneficial 
effect of nicotine in ulcerative colitis we examined 
the effect of nicotine on the production of two 
important mediators of inflammation in inflamma- 
tory bowel disease, interleukin 2 (IL-2) and tumour 
necrosis factor-e~ (TNFo~). 
2. Materials and methods 
Approval lbr this study was obtained from the 
Medical Ethical Committee of the University Hospi- 
tal of Rotterdam. 
2.1. Isolation of mononuclear cells 
Mononuclear cells (MNC) were isolated from 60 
mi heparinized venous blood immediately after blood 
sampling. The method used was a modification of 
the technique described by Boyum (Boyum, 1968). 
Briefly, the blood was diluted 1:1 with Phosphate 
Buffered Saline (PBS; Oxoid, UK) before fractioning 
it by a one-step Ficoll-Paque gradient (Pharmacia, 
Sweden) centrifugation at l l00 x g for 15 min at 
20°C. The interphase was washed in PBS and resus- 
pended in Dulbecco's Modified Eagles Medium 
(DMEM) containing HEPES and foetal calf serum 
(Gibco, UK), supplemented with penicillin and 
streptomycin (Flow Lab, UK). 
Following isolation the MNC were incubated in 
culture medium for 90 min in a water saturated 
atmosphere of 37°C containing 5% CO 2. Non-adher- 
ent MNC were harvested by repeated rinsing of the 
culture flasks (Costar, USA) with DMEM. The via- 
bility of the cells, assessed by Trypan blue exclusion, 
was over 95%. 
2.2. Characterization of non-adherent mononuclear 
cell fraction 
The leucocyte subpopulations present in the non- 
adherent MNC fraction were analyzed by FACS 
using the monoclonal antibodies Leu 4, Leull and 
Leu 19 (Becton Dickinson, Mountain View, CA) that 
recognize CD3, CD16 and CD19, respectively. CD14 
and CD20 positive cells were characterized by My 4 
and B4 (Coulter Cytometry, Florida). 
2.3. Stimulation experiments 
Non-adherent MNC were cultured (2 x 106 cells/ 
well) in 24 wells culture plates (Costar, Cambridge 
MA, USA) in the absence or presence of varying 
concentrations of nicotine-hydrogen-tartrate (BDH, 
Poole, UK) or prednisolone-di-sodium-phosphate 
(Genfarma, The Netherlands) for 24 h, followed by 
addition of phytohemagglutinin (PHA: 10 i~g/ml; 
Sigma, Belgium). After incubation for another 24 
hours supernatants were harvested and stored at 
-80°C until IL-2 and TNFa concentrations werc 
assessed by ELISA (IL-2: Medgenix, Belgium, sensi- 
tivity: 70 pg/ml and TNFo~: CLB, The Netherlands, 
sensitivity: 3 pg/ml). The concentration f IL-2 and 
TNFe~ produced in the presence of PHA and absence 
of nicotine and prednisolone was used as control and 
set at 100%. All incubations were performed in 
duplicate. 
2.4. Statistics 
The IL-2 and TNFe~ production are expressed as 
mean + SEM (n --- 5). 
Statistical comparisons between control and 
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drug-treated cell cultures were made by paired t-test. 
A p < 0.05 was considered to be significant. 
3. Results 
The non-adherent MNC fraction consisted primar- 
ily of T-lymphocytes (Table 1). The PHA-stimulated 
TNFa  production ranged from 3580 to 5430 pg /ml ,  
with a mean-t -SEM of 4585-t-360 pg /ml  and a 
median of 4810 pg /ml .  For IL-2 we measured a 
range of 1000-2660 pg/ml ,  with a mean of 1615 + 
295 pg /ml  and a median of 1590 pg /ml .  
The production of IL-2 and TNFa  by these cells 
was inhibited in a dose dependent manner when 
nicotine was added 24 h prior to PHA (Fig. 1). This 
inhibition was only partial. For IL-2 the maximum 
effect of nicotine was observed at 10-7 M (Fig. l a) 
and for TNFa  at 10 -8 M (Fig. lb). A further 
increase of the nicotine concentration did not en- 
hance the effect. There was a considerable interindi- 
viduai variation in response to nicotine but enhanced 
production of the cytokines after addition of nicotine 
was never observed. 
Addition of nicotine and PHA simultaneously or 
addition of nicotine after PHA, in contrast, had no 
effect on IL-2 and TNFcx production. Nicotine did 
not influence the viability of the cells, even in the 
highest concentration used (10 -~ M). 
Treatment of the non-adherent MNC with the 
corticosteroid prednisolone, also caused a dose de- 
pendent inhibition of IL-2 and TNFa  production. As 
with nicotine, the addition of prednisolone had to 
proceed that of PHA in order to cause a significant 
inhibition of IL-2 and TNFo~ production at the lower 
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Fig. 1. Effects of nicotine (solid dot) and prednisolone (open 
triangle) on the synthesis of interleukin 2 (a) and tumour necrosis 
factor-et (b) in cultures of human peripheral blood lymphocytes 
stimulated with phytohemagglutinin (PHA: 10 I~g/ml). Cytokine 
production (percentage of control) is presented as mean _+ SEM 
(vertical bars) and represent 5 experiments performed on non 
adherent mononuclear cells obtained from 5 separate healthy 
volunteers. The paired t-test was used to compare control and 
drug-treated cell cultures. Prednisolone and nicotine caused a 
significant inhibition of cytokine production, " p < 0.05; " " p < 
0.01 compared with control cultures incubated with DMEM and 
PHA. 
Table 1 
Non-adherent mononuclear cell fraction 
Cluster differentiation Percentage 
CD3 72.1 + 2.3 
CDI6/CD56 15.1 + 0.8 
CD20 7.3 _+ 1.9 
CDI4 0.6+0.1 
Not classified 4.9 + 1.2 
doses. In contrast to nicotine, the effect of pred- 
nisolone did not reach a plateau at the concentrations 
tested. 
4. Discussion 
Percentage of different cell types comprising the non-adherent 
mononuclear cells. 
Cells were characterized by FACS using the monoclonal antibod- 
ies Leu 14, Leu 11, Leul9, B4 and My 4. 
The results of this study show that nicotine in- 
hibits the in vitro production of IL-2 and TNFot by 
human non-adherent MNC. This is in agreement 
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with our recent observation of an inhibition of cy- 
tokine production by mouse colonic mucosa after 
treatment with nicotine (van Dijk et al., 1995). 
The inhibition of IL-2 and TNFa production by 
human MNC appears to be dependent on the concen- 
tration of nicotine, the duration of incubation and the 
individual donor. The potency of nicotine, however, 
was about 50% of that of prednisolone, a potent 
glucocorticosteroid. It is at present not clear whether 
nicotine administered transdermally is less effective 
clinically than prednisolone, as the clinical observa- 
tion by Pullan et al. (1994) was on an additional 
anti-inflammatory effect of nicotine added to mainte- 
nance therapy with corticosteroids or 5-aminosali- 
cylic acid, in the treatment of ulcerative colitis. In 
this study, nicotine reached its maximum effect at 
concentrations equivalent to those measured in 
plasma of smokers (Bowman and Rand, 1980). 
We chose to use a cell population consisting 
predominantly of T-cells in this study for two rea- 
sons. Recent study has proven cyclosporin to be 
effective in the treatment of ulcerative colitis refrac- 
tory to steroid therapy (Lichtiger et al., 1994). Cy- 
closporin exerts its immunosuppressive effect by 
suppressing the induction and amplification of T-cell 
responses by inhibiting cytokine gene activation, par- 
ticularly IL-2 (Schreiber and Crabtree. 1992). An- 
other finding indicating an important role for the 
T-cell in the pathogenesis of ulcerative colitis is the 
observation that appendectomy has a protective f- 
fect against ulcerative colitis. The appendix is a 
helper T-cell organ (Rutgeerts et al., 1994). 
Inhibition of TNFo~ production by nicotine offers 
not only a possible explanation for the beneficial 
effect of this drug in UC but could also shed some 
light on the role smoking plays in the development 
of cancer. Smoking does not only elevate the risk of 
lung cancer but also of cancer in organs which do 
not come in contact with smoke itself (Heineman et 
ai., 1994; Viscoli et al., 1993; Sood, 1991). A possi- 
ble contributory factor to this carcinogenic effect of 
smoke 'at a distance' is that nicotine causes a more 
or less general suppression of the immune system, 
rendering the individual more susceptible for the 
development of neoplasms. 
We conclude that nicotine has immunoregulatory 
effects through modulation of the cytokine produc- 
tion by non-adherent mononuclear cells. 
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